[go: up one dir, main page]

MX2013011184A - Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. - Google Patents

Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.

Info

Publication number
MX2013011184A
MX2013011184A MX2013011184A MX2013011184A MX2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A MX 2013011184 A MX2013011184 A MX 2013011184A
Authority
MX
Mexico
Prior art keywords
compositions
methods
diseases
surveilling
diagnosing
Prior art date
Application number
MX2013011184A
Other languages
English (en)
Other versions
MX352296B (es
Inventor
Richard Morgan
Original Assignee
Hox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hox Therapeutics Ltd filed Critical Hox Therapeutics Ltd
Publication of MX2013011184A publication Critical patent/MX2013011184A/es
Publication of MX352296B publication Critical patent/MX352296B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G01N33/57515—
    • G01N33/5752—
    • G01N33/57555—
    • G01N33/5759—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Las composiciones y los métodos con los cuales se puede inhibir la expresión del gen de la proteína TMEM92 o que inhiben la función de la proteína TMEM92 de muerte pueden utilizarse para tratar, diagnosticar y vigilar enfermedades, por ejemplo, cáncer.
MX2013011184A 2011-03-28 2012-03-28 Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades. MX352296B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105129.9A GB201105129D0 (en) 2011-03-28 2011-03-28 Compositions and methods for treating, diagnosing and monitoring disease
PCT/GB2012/000285 WO2012131301A1 (en) 2011-03-28 2012-03-28 Compositions and methods for treating, diagnosing and monitoring disease

Publications (2)

Publication Number Publication Date
MX2013011184A true MX2013011184A (es) 2014-03-12
MX352296B MX352296B (es) 2017-11-17

Family

ID=44067442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011184A MX352296B (es) 2011-03-28 2012-03-28 Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.

Country Status (16)

Country Link
US (1) US9803196B2 (es)
EP (1) EP2691526B1 (es)
JP (1) JP6158785B2 (es)
KR (1) KR20140045345A (es)
CN (1) CN103502453B (es)
AU (1) AU2012235986B2 (es)
BR (1) BR112013025113A2 (es)
CA (1) CA2831481A1 (es)
DK (1) DK2691526T3 (es)
ES (1) ES2635393T3 (es)
GB (1) GB201105129D0 (es)
IL (1) IL228581A (es)
MX (1) MX352296B (es)
RU (1) RU2013143373A (es)
WO (1) WO2012131301A1 (es)
ZA (1) ZA201307890B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108085388B (zh) * 2017-12-27 2020-04-10 固安博健生物技术有限公司 一种与骨肉瘤发生发展相关的基因及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507549B2 (en) 1997-03-07 2009-03-24 Siemens Healthcare Diagnostices, Inc. Method for following the progress of prostate cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
WO2002078516A2 (en) 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2002086069A2 (en) 2001-04-20 2002-10-31 Incyte Genomics, Inc. Secreted proteins
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
JP2010523990A (ja) * 2007-04-12 2010-07-15 プロテオシス アクチエンゲゼルシャフト アネキシンａ３による前立腺癌の自己免疫制御
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases

Also Published As

Publication number Publication date
US20140154238A1 (en) 2014-06-05
WO2012131301A1 (en) 2012-10-04
CN103502453A (zh) 2014-01-08
GB201105129D0 (en) 2011-05-11
RU2013143373A (ru) 2015-05-10
CA2831481A1 (en) 2012-10-04
BR112013025113A2 (pt) 2016-11-22
KR20140045345A (ko) 2014-04-16
DK2691526T3 (en) 2017-08-28
CN103502453B (zh) 2017-06-09
AU2012235986A1 (en) 2013-10-17
ZA201307890B (en) 2014-07-30
NZ615915A (en) 2015-08-28
EP2691526B1 (en) 2017-05-10
JP6158785B2 (ja) 2017-07-05
JP2014511845A (ja) 2014-05-19
MX352296B (es) 2017-11-17
IL228581A (en) 2017-07-31
ES2635393T3 (es) 2017-10-03
EP2691526A1 (en) 2014-02-05
AU2012235986B2 (en) 2017-05-04
IL228581A0 (en) 2013-12-31
US9803196B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX394516B (es) Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CO2017004728A2 (es) Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa)
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
CR20170478A (es) Compuestos novedosos
NI201600071A (es) Compuestos de inhibidor de autotaxina
CO6950476A2 (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
NI201400046A (es) AGENTES iARN, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
BR112016023558A2 (pt) compostos úteis como imunomoduladores
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
ECSP14030779A (es) Inhibidores del nampt
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
MX2015003701A (es) Composiciones para tratamiento.

Legal Events

Date Code Title Description
FG Grant or registration